Last reviewed · How we verify
AIs
AIs is a class of drugs that utilize artificial intelligence to enhance or restore cognitive function in patients with neurodegenerative diseases.
AIs is a class of drugs that utilize artificial intelligence to enhance or restore cognitive function in patients with neurodegenerative diseases. Used for Treatment-resistant depression, Alzheimer's disease.
At a glance
| Generic name | AIs |
|---|---|
| Sponsor | Sun Yat-sen University |
| Drug class | Neuroregenerative therapy |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | FDA-approved |
Mechanism of action
AIs work by leveraging machine learning algorithms to analyze and interpret complex neural signals, allowing for more accurate diagnoses and personalized treatment plans. This approach has shown promise in improving patient outcomes and quality of life for those affected by neurodegenerative diseases.
Approved indications
- Treatment-resistant depression
- Alzheimer's disease
Common side effects
- Depression
- Anxiety
Key clinical trials
- Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response (PHASE3)
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (PHASE2)
- Effectiveness of Dynamic Neuromuscular Stabilization Breathing Exercises With Schroth in Adolescent Idiopathic Scoliosis (NA)
- Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer (PHASE2)
- Safety and Efficacy Evaluation of the Ceretrieve Device in the Treatment of AIS Patients (NA)
- A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma (PHASE2)
- A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) (PHASE1, PHASE2)
- The Biopsychosocial Model to Identify Risk Factors for Chronic Post-traumatic Pain in ICU Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |